BC
PACB icon

Broadfin Capital’s Pacific Biosciences PACB Stock Holding History

Broadfin Capital’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,493,021
Closed -$13.5M – 56
2018
Q3 		$13.5M Buy
2,493,021
+1,438,930
+137% +$6.17M 1.98% 18
2018
Q2 		$3.74M Buy
+1,054,091
New +$2.92M 0.59% 38

Other funds holding PACB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Broadfin Capital's PACB Position: Q4 2018 in Review

Broadfin Capital sold out of Pacific Biosciences (PACB) in Q4 2018, closing a stake of 2,493,021 shares — an estimated $13.5M sold.

Broadfin Capital first reported a position in PACB in Q2 2018 and held it in 2 quarters. The position peaked at $13.5M in Q3 2018. 155 funds tracked by Wall St. Rank hold PACB as of Q4 2018.

  • Broadfin Capital reported no remaining Pacific Biosciences position as of Q4 2018 after selling out during the quarter.
  • Broadfin Capital sold 2,493,021 Pacific Biosciences shares in Q4 2018, an estimated $13.5M.
  • Broadfin Capital first reported a position in Pacific Biosciences in Q2 2018 and held it in 2 quarters.
  • Broadfin Capital's Pacific Biosciences position peaked at $13.5M in Q3 2018.
  • 155 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2018.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.